Sunday, June 25, 2017 11:54:08 AM
AVEO...June 23 (Reuters) - European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market. The drug was also backed for treating adult patients with advanced kidney cancer who met certain criteria and had received one prior treatment with cytokine therapy, the EMA said.
07/31? ...FDA "Futility" analysis due mid-2017...Topline data due 1Q 2018
60minute
Daily
AVEO kidney cancer
07/31? ...FDA "Futility" analysis due mid-2017...Topline data due 1Q 2018
60minute
Daily
AVEO kidney cancer
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
